TY  - JOUR
AU  - Nadal, E
AU  - Bosch-Barrera, J
AU  - Cedrés, S
AU  - Coves, J
AU  - García-Campelo, R
AU  - Guirado, M
AU  - López-Castro, R
AU  - Ortega, A L
AU  - Vicente, D
AU  - de Castro-Carpeño, J
PY  - 2021
DO  - 10.1007/s12094-020-02532-2
UR  - http://hdl.handle.net/10668/17102
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in...
LA  - en
KW  - Clinical guidelines
KW  - Diagnostic
KW  - Malignant pleural mesothelioma
KW  - Treatment
KW  - Antineoplastic Agents
KW  - Asbestos
KW  - Carcinogens
KW  - Combined Modality Therapy
KW  - Cytoreduction Surgical Procedures
KW  - Deoxycytidine
KW  - Genetic Testing
KW  - High-Throughput Nucleotide Sequencing
KW  - Humans
KW  - Immunotherapy
KW  - Medical Oncology
KW  - Mesothelioma, Malignant
KW  - Neoplasm Staging
KW  - Pemetrexed
KW  - Platinum Compounds
KW  - Pleural Neoplasms
KW  - Radiotherapy
KW  - Societies, Medical
KW  - Spain
KW  - Vinorelbine
KW  - Gemcitabine
TI  - SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
TY  - research article
VL  - 23
ER  -